Gianni Chessari
Astex Pharmaceuticals · 135 works · 4,353 citations · h-index 29
Top works
- Diverse, High-Quality Test Set for the Validation of Protein−Ligand Docking Performance
- Recent Developments in Fragment-Based Drug Discovery
- Modeling Water Molecules in Protein−Ligand Docking Using GOLD
- Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency
- Application of Fragment-Based Lead Generation to the Discovery of Novel, Cyclic Amidine β-Secretase Inhibitors with Nanomolar Potency, Cellular Activity, and High Ligand Efficiency
- From fragment to clinical candidate—a historical perspective
- Trisubstituted Acridine Derivatives as Potent and Selective Telomerase Inhibitors
- Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design
- Application of Fragment Screening by X-ray Crystallography to the Discovery of Aminopyridines as Inhibitors of β-Secretase
- Application of Fragment Screening by X-ray Crystallography to β-Secretase
- Quantitative Determination of Intermolecular Interactions with Fluorinated Aromatic Rings
- Application of Fragment Screening and Fragment Linking to the Discovery of Novel Thrombin Inhibitors
- An Evaluation of Force-Field Treatments of Aromatic Interactions
- Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function
- Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP
- Accelerated Chemical Reaction Optimization Using Multi-Task Learning
- High Resolution Magic Angle Spinning NMR in Combinatorial Chemistry
- Noncovalent Functional‐Group–Arene Interactions
- Discovery of a Potent Nonpeptidomimetic, Small-Molecule Antagonist of Cellular Inhibitor of Apoptosis Protein 1 (cIAP1) and X-Linked Inhibitor of Apoptosis Protein (XIAP)
- Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator